Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug;154(2):447-457.
doi: 10.1016/j.jaci.2024.04.017. Epub 2024 Apr 30.

Structural analysis of human IgE monoclonal antibody epitopes on dust mite allergen Der p 2

Affiliations

Structural analysis of human IgE monoclonal antibody epitopes on dust mite allergen Der p 2

Alyssa Ball et al. J Allergy Clin Immunol. 2024 Aug.

Abstract

Background: Human IgE (hIgE) mAbs against major mite allergen Der p 2 developed using human hybridoma technology were used for IgE epitope mapping and analysis of epitopes associated with the hIgE repertoire.

Objective: We sought to elucidate the new hIgE mAb 4C8 epitope on Der p 2 and compare it to the hIgE mAb 2F10 epitope in the context of the allergenic structure of Der p 2.

Methods: X-ray crystallography was used to determine the epitope of anti-Der p 2 hIgE mAb 4C8. Epitope mutants created by targeted mutagenesis were analyzed by immunoassays and in vivo using a human high-affinity IgE receptor (FcεRIα)-transgenic mouse model of passive systemic anaphylaxis.

Results: The structure of recombinant Der p 2 with hIgE mAb 4C8 Fab was determined at 3.05 Å. The newly identified epitope region does not overlap with the hIgE mAb 2F10 epitope or the region recognized by 3 overlapping hIgE mAbs (1B8, 5D10, and 2G1). Compared with wild-type Der p 2, single or double 4C8 and 2F10 epitope mutants bound less IgE antibodies from allergic patients by as much as 93%. Human FcεRIα-transgenic mice sensitized by hIgE mAbs, which were susceptible to anaphylaxis when challenged with wild-type Der p 2, could no longer cross-link FcεRI to induce anaphylaxis when challenged with the epitope mutants.

Conclusions: These data establish the structural basis of allergenicity of 2 hIgE mAb nonoverlapping epitopes on Der p 2, which appear to make important contributions to the hIgE repertoire against Der p 2 and provide molecular targets for future design of allergy therapeutics.

Keywords: IgE; anaphylaxis; antibody; epitope; house dust mite.

PubMed Disclaimer

Conflict of interest statement

Disclosure statement Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) (award nos. R01AI077653-13 [to A.P., M.D.C., and M.C.] and R01AI155668 and R21AI123307 [to S.A.S.]). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The research was supported in part by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences (Z01-ES102906 [to G.A.M.]). The structural results shown in this report are derived from data collected at Southeast Regional Collaborative Access Team (SER-CAT; 22ID) beamline at the Advanced Photon Source, Argonne National Laboratory. Supporting institutions may be found at www.ser-cat.org/members.html. Use of the Advanced Photon Source was supported by the US Department of Energy, Office of Science, Office of Basic Energy Sciences (contract nos. DE-AC02-06CH11357 and W-31-109-Eng-38). This work was partially supported by an ASPIRE III grant from the Office of the Vice President of Research at the University of South Carolina. This research is funded by the above mentioned NIH/NIAID award to InBio. Disclosure of potential conflict of interest: A. Pomés is an employee of InBio; and is the contact principal investigator of the NIH R01 award that provided funding for the study. M.D. Chapman is an employee of InBio; has a financial interest in InBio; and is a co-investigator on the NIH R01 award. A. Ball is an employee of InBio. The hIgE mAbs and some of the allergens described herein were produced by InBio. InBio has a license agreement with the VUMC for commercialization of hIgE mAbs for research and diagnostic purposes. The hIgE mAbs covered by this agreement are available from InBio (www.inbio.com). S.A. Smith is an inventor on US patent 10908168-B2 for generation of hIgE mAbs; has received patent royalties; and has related patents pending. The rest of the authors declare that they have no relevant conflicts of interest.

Figures

Figure 1:
Figure 1:
A. Der p 2 is shown in magenta, and the Fab heavy chain and light chain are shown in blue and green, respectively. B. Epitope residues of Der p 2 and 4C8 Fab CDR residues of heavy and light chain are in stick representation. Residue interactions are shown by black dashes. C. X-ray crystal structure of hIgE 4C8 Fab, heavy chain is shown in blue and light chain in green, with each CDR represented by different colors. D. The heavy and light chain CDRs in a space-filling representation. E. The superimposition of structures of Der p 2 in complex with 4C8 (blue), 2F10 (grey) and 7A1 (green). F. Surface representation of rDer p 2 with epitope region of 4C8 (blue), 2F10 (grey), and 7A1 (green). The overlapping residues between 2F10 and 7A1 Fab are teal.
Figure 2:
Figure 2:
A. Total interface area of complexes Der p 2–7A1 (PDB:6OY4), Der p 2–2F10 (PDB:7MLH) and Der p 2– 4C8 Fabs (PDB:8VK1). The areas contributed by the heavy and light chains are shown in blue and green, respectively. B. H-bonds formed by heavy chain (blue) and light chain (green) in the complexes of Der p 2 with 7A1, 2F10 and 4C8 antibodies, respectively.
Figure 3:
Figure 3:
A. Inhibition of hIgE mAb 2F10 binding to rDer p 2 by rDer p 2, 2F10 epitope mutant, 4C8 epitope mutant, or 4C8–2F10 double epitope mutant. B. Inhibition of hIgE mAb 4C8 binding to rDer p 2 by rDer p 2, 2F10 epitope mutant, 4C8 epitope mutant, or 4C8–2F10 double epitope mutant.
Figure 4:
Figure 4:
Dose-response curves of hIgE mAb binding to Der p 2 wild-type and 4C8 epitope mutant (AAS), 2F10 epitope mutant (KKD), and double 4C8–2F10 epitope mutant (AAS-KK). Data are averages of 2–3 experiments ± SD.
Figure 5:
Figure 5:
Inhibition of polyclonal IgE Ab binding from mite-allergic subjects to Der p 2 by 4C8 epitope mutant (AAS), 2F10 epitope mutant (KKD), and double 4C8–2F10 epitope mutant (AAS-KK). Plasma from the mite-allergic subject from which hIgE mAb 4C8 was derived is designated as “S”. Plasma from the mite-allergic subjects is designated as “PL”. Data are averages of duplicates ± SD.
Figure 6:
Figure 6:
Human FcεRIα–transgenic mice were sensitized with human Der p 2–specific IgE mAbs 2F10 + 4C8, 2F10 + 2G1, or 2F10 + 4C8 + 2G1. Animals were challenged with rDer p 2 wildtype or mutant antigen. Anaphylaxis was monitored using an implanted temperature probe for 90 min following challenge. Time points with calculated P values <0.05 are underscored with a colored bar. Data are means ± SD of each experimental group. The number of mice (n) for each experimental group is shown in parenthesis. The number of mice in each group that succumb from anaphylaxis are indicated by an asterisk.

Similar articles

Cited by

References

    1. Platts-Mills TA, Vervloet D, Thomas WR, Aalberse RC, Chapman MD. Indoor allergens and asthma: report of the third international workshop. J Allergy Clin Immunol. 1997;100(6 Pt 1):S2–24. - PubMed
    1. Mueller GA, Randall TA, Glesner J, Pedersen LC, Perera L, Edwards LL, et al. Serological, genomic and structural analyses of the major mite allergen Der p 23. Clin Exp Allergy. 2016;46(2):365–76. - PMC - PubMed
    1. Khatri K, Richardson CM, Glesner J, Kapingidza AB, Mueller GA, Zhang J, et al. Human IgE monoclonal antibody recognition of mite allergen Der p 2 defines structural basis of an epitope for IgE cross-linking and anaphylaxis in vivo. PNAS Nexus. 2022;1(3):pgac054. - PMC - PubMed
    1. Batard T, Baron-Bodo V, Martelet A, Le Mignon M, Lemoine P, Jain K, et al. Patterns of IgE sensitization in house dust mite-allergic patients: implications for allergen immunotherapy. Allergy. 2016;71(2):220–9. - PubMed
    1. Posa D, Perna S, Resch Y, Lupinek C, Panetta V, Hofmaier S, et al. Evolution and predictive value of IgE responses toward a comprehensive panel of house dust mite allergens during the first 2 decades of life. J Allergy Clin Immunol. 2017;139(2):541–9 e8. - PubMed